| __timestamp | Amicus Therapeutics, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 22570000 |
| Thursday, January 1, 2015 | 47269000 | 24378000 |
| Friday, January 1, 2016 | 71151000 | 26621000 |
| Sunday, January 1, 2017 | 88671000 | 28653000 |
| Monday, January 1, 2018 | 127200000 | 37734000 |
| Tuesday, January 1, 2019 | 169861000 | 41884000 |
| Wednesday, January 1, 2020 | 156407000 | 64435000 |
| Friday, January 1, 2021 | 192710000 | 57483000 |
| Saturday, January 1, 2022 | 213041000 | 70062000 |
| Sunday, January 1, 2023 | 275270000 | 52790000 |
Cracking the code
In the competitive landscape of biotechnology, effective cost management is crucial. Amicus Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
Since 2014, Amicus Therapeutics has seen a consistent rise in SG&A expenses, peaking in 2023 with a 1,230% increase from 2014. This growth reflects their aggressive expansion and investment in operational capabilities.
Conversely, Ligand Pharmaceuticals has maintained a more stable SG&A trajectory, with a modest 134% increase over the same period. This suggests a strategic focus on cost efficiency while still supporting growth.
Understanding these trends offers valuable insights into how these companies manage their operational costs, providing a window into their strategic priorities and market positioning.
Comparing SG&A Expenses: GSK plc vs Ligand Pharmaceuticals Incorporated Trends and Insights
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.